A maculopapular-type eruption associated with deferasirox administration

Ohshita, Akifumi; Nakai, Noriaki; Katoh, Norito; Konishi, Kazuo

doi:10.1016/j.jaad.2013.07.015

Cited by 7 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported a maculopapular eruption due to deferasirox demonstrating intraepidermal lymphocytic infiltration, epidermal spongiosis, partial vaculoar degeneration at the dermal-epidermal interface, and mild lymphocytic infiltration in the upper dermis. 3 In addition, skin rash with deferasirox therapy was reported in the several observational studies. 8 , 9 …”

Section: Discussionmentioning

confidence: 99%

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome

Polat¹,

Belli

Karakuş

et al. 2017

An. Bras. Dermatol.

View full text Add to dashboard Cite

Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case of myelodysplastic syndrome with urticarial vasculitis due to deferasirox therapy. Drug eruption was been confirmed by means of a challenge test, together with histopathological and clinical findings. To the best of our knowledge, we report the first case of deferasirox-induced urticarial vasculitis. Physicians should be aware of the possibility of urticarial vasculitis on deferasirox therapy and the fact that the discontinuation of the drug generally results in improvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome

Polat¹,

Belli

Karakuş

et al. 2017

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…After the dechallenge of this drug, the symptoms subsided. However, the rechallenge of the drug was not done in this patient [ 7 ]. Sompornrattanaphan et al reported a case of deferasirox-induced type 1 hypersensitivity reaction.…”

Section: Discussionmentioning

confidence: 99%

First Case Report of Deferiprone-Induced Anaphylactic Reaction

Bumrungratanayos,

Tungjitviboonkun

2024

Cureus

View full text Add to dashboard Cite

A 56-year-old Thai male, known for allergies to penicillin, sulfa, and lincosamide, presented with hyperferritinemia. Upon initiating deferiprone therapy, the patient experienced recurrent episodes of dyspnea, culminating in anaphylactic shock. Treatment included subcutaneous epinephrine, intravenous chlorpheniramine, and hydrocortisone, which led to symptom resolution. This case constitutes the first case report of deferiprone-associated anaphylactic reactions.

show abstract

“…[ 7 ] A maculopapular rash with deferasirox has also been reported in a 75-year-old female, a case of acute myeloid leukemia who had received frequent blood transfusions. [ 8 ] On causality assessment, the association between the offending drug and the suspected adverse drug reaction was found to be probable on the WHO-UMC scale because, on dechallenge, the reaction subsided and rechallenge was not attempted because of the fear of possible anaphylactic reaction. According to the Hartwig severity assessment scale, the reaction was found to be level 3 (moderate) in severity.…”

Section: Discussionmentioning

confidence: 99%

Hypersensitivity reaction with deferasirox

Sharma

Arora

Singh

2015

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Thalassemias comprise a group of hereditary blood disorders. Thalassemia major presents with anemia within the first 2 years of life requiring frequent blood transfusions for sustaining life. Regular blood transfusions lead to iron overload-related complications. Prognosis of thalassemia has improved because of the availability of iron-chelating agents. Oral iron chelators are the mainstay of chelation therapy. Deferasirox is a new-generation oral iron chelator for once daily usage. We herein describe a patient of beta thalassemia major who developed an allergic manifestation in the form of erythematous pruritic skin rashes to the oral iron chelator deferasirox. This is a rare adverse reaction reported with deferasirox that led to a therapeutic dilemma in this particular case.

show abstract

A maculopapular-type eruption associated with deferasirox administration

Cited by 7 publications

References 3 publications

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome

First Case Report of Deferiprone-Induced Anaphylactic Reaction

Hypersensitivity reaction with deferasirox

Contact Info

Product

Resources

About